Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28265742 | 0.84 | TLR8 (0.46) | HRH4ROCK1TLR8PTGDR | |
| SCHEMBL17315505 | 0.83 | NUDT1 (0.55) | HRH4ROCK1TLR8PTGDR | |
| SCHEMBL28152083 | 0.83 | HRH4 (0.68) | HRH4TLR8TP53MAPT | |
| SCHEMBL28267602 | 0.82 | HRH4 (0.47) | HRH4TLR8PTGS2 | |
| SCHEMBL17315393 | 0.82 | ROCK1 (0.44) | HRH4ROCK1TLR8PTGDR | |
| SCHEMBL28151083 | 0.81 | CA1 (0.49) | HRH4ROCK1TLR8 | |
| SCHEMBL28151094 | 0.81 | HRH4 (0.51) | HRH4ROCK1TLR8PTGDRTP53 | |
| SCHEMBL28267163 | 0.81 | PTGDR (0.48) | HRH4TLR8PTGDRPTGS2 | |
| SCHEMBL17315300 | 0.81 | NUDT1 (0.56) | HRH4ROCK1TLR8PTGDR | |
| SCHEMBL28265648 | 0.81 | HRH4 (0.46) | HRH4TLR8TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106794181-A | MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions | 托马斯·黑勒戴药物研究基金会 | 2017-05-31 | — | — | CN | disclosed |